Neurovalens develops non-invasive neurostimulation wearables designed to treat sleep, mental health, and metabolic conditions through vestibular stimulation. The company’s Modius devices deliver electrical stimulation to the vestibular nerve via a wearable headset. Its approach focuses on influencing central brain circuits involved in sleep regulation, stress response, and metabolic control. Neurovalens positions its technology within regulated clinical treatment pathways.

The technology applies targeted electrical stimulation to the vestibular system, which plays a role in autonomic regulation and energy balance. By modulating vestibular input, the system aims to influence downstream brain networks associated with sleep, anxiety, and metabolism. Treatment protocols are designed for repeated, at-home use and supported by companion software. This approach avoids invasive procedures while delivering structured neuromodulation therapy.

Neurovalens targets individuals with insomnia, anxiety, and metabolic disorders seeking non-pharmacological treatment options. The Modius devices are cleared for clinical use and intended to complement existing medical care. Its positioning reflects broader interest in wearable neuromodulation therapies that leverage peripheral nerve pathways to address central neurological and physiological conditions.